{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Canagliflozin 100 mg",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Participants receive canagliflozin 100 mg orally once daily (QD) before the first meal of the day."
      },
      {
        "id": "arm_2",
        "name": "Placebo",
        "type": {
          "code": "Placebo Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Placebo Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Participants receive matching placebo capsules orally once daily (QD) before the first meal of the day."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_9",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_9"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_10",
        "armId": "arm_2",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_10"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "CKD Stage 3",
        "instanceType": "StudyCohort",
        "characteristic": "eGFR >=30 to <60 mL/min/1.73m2 (Targeting approximately 60% of total population)"
      },
      {
        "id": "cohort_2",
        "name": "CKD Stage 2",
        "instanceType": "StudyCohort",
        "characteristic": "eGFR >=60 to <90 mL/min/1.73m2 (Targeting approximately 40% of total population)"
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Canagliflozin 100 mg - Prescreening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Canagliflozin 100 mg during Prescreening"
      },
      {
        "id": "elem_2",
        "name": "Canagliflozin 100 mg - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Canagliflozin 100 mg during Screening"
      },
      {
        "id": "elem_3",
        "name": "Canagliflozin 100 mg - Single-Blind Placebo Run-In",
        "instanceType": "StudyElement",
        "description": "Treatment period for Canagliflozin 100 mg during Single-Blind Placebo Run-In"
      },
      {
        "id": "elem_4",
        "name": "Canagliflozin 100 mg - Double-Blind Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Canagliflozin 100 mg during Double-Blind Treatment Phase"
      },
      {
        "id": "elem_5",
        "name": "Canagliflozin 100 mg - Post-Treatment Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Canagliflozin 100 mg during Post-Treatment Follow-up"
      },
      {
        "id": "elem_6",
        "name": "Placebo - Prescreening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo during Prescreening"
      },
      {
        "id": "elem_7",
        "name": "Placebo - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo during Screening"
      },
      {
        "id": "elem_8",
        "name": "Placebo - Single-Blind Placebo Run-In",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo during Single-Blind Placebo Run-In"
      },
      {
        "id": "elem_9",
        "name": "Placebo - Double-Blind Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo during Double-Blind Treatment Phase"
      },
      {
        "id": "elem_10",
        "name": "Placebo - Post-Treatment Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo during Post-Treatment Follow-up"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 10,
      "cohortCount": 2,
      "elementCount": 10
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Double Blind",
        "codeSystem": "USDM",
        "decode": "Double Blind"
      },
      "maskedRoles": [
        "Subject",
        "Investigator",
        "Outcome Assessor"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "1:1"
      },
      "stratificationFactors": [
        "Pretreatment eGFR (30 to <45, 45 to <60, 60 to <90 mL/min/1.73m2)"
      ],
      "controlType": {
        "code": "Placebo Control",
        "codeSystem": "USDM",
        "decode": "Placebo Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Nephrology",
        "Endocrinology",
        "Cardiovascular"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Double Blind",
        "maskedRoles": [
          "Subject",
          "Investigator",
          "Outcome Assessor"
        ]
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "1:1",
        "stratificationFactors": [
          "Pretreatment eGFR (30 to <45, 45 to <60, 60 to <90 mL/min/1.73m2)"
        ]
      },
      "controlType": "Placebo",
      "therapeuticAreas": [
        "Nephrology",
        "Endocrinology",
        "Cardiovascular"
      ]
    },
    "arms": [
      {
        "name": "Canagliflozin 100 mg",
        "type": "Experimental Arm",
        "description": "Participants receive canagliflozin 100 mg orally once daily (QD) before the first meal of the day.",
        "isTitration": false
      },
      {
        "name": "Placebo",
        "type": "Placebo Comparator",
        "description": "Participants receive matching placebo capsules orally once daily (QD) before the first meal of the day.",
        "isTitration": false
      }
    ],
    "cohorts": [
      {
        "name": "CKD Stage 3",
        "characteristic": "eGFR >=30 to <60 mL/min/1.73m2 (Targeting approximately 60% of total population)"
      },
      {
        "name": "CKD Stage 2",
        "characteristic": "eGFR >=60 to <90 mL/min/1.73m2 (Targeting approximately 40% of total population)"
      }
    ],
    "epochs": [
      {
        "name": "Prescreening",
        "description": "Assessment of eGFR and UACR based on local laboratory results within 6 months prior to screening."
      },
      {
        "name": "Screening",
        "description": "Up to 8 weeks period to assess eligibility and stabilize background ACEi/ARB therapy."
      },
      {
        "name": "Single-Blind Placebo Run-In",
        "description": "2-week period (Week -2 to Day 1) where subjects take single-blind placebo to assess compliance."
      },
      {
        "name": "Double-Blind Treatment Phase",
        "description": "Randomized treatment period starting at Day 1 until the Global Trial End Date (GTED), estimated 5 to 5.5 years."
      },
      {
        "name": "Post-Treatment Follow-up",
        "description": "Telephone contact or visit approximately 30 days after the last dose of study drug."
      }
    ]
  }
}